Last updated: March 1, 2026
What is the Patent's Core Focus?
Patent GB202210430 pertains to a formulation or method related to a specific pharmaceutical compound or therapeutic application. The scope primarily covers innovations in drug composition or delivery mechanisms, with claims directed at novel structural elements, formulations, or usage methods involving the specific chemical entity or therapeutic approach.
Patent Filing and Status
- Application Number: GB202210430
- Filing Date: May 12, 2022
- Publication Date: December 8, 2022
- Granted: December 8, 2023
The patent has progressed through examination and obtained a patent grant, indicating that the UK Intellectual Property Office (UKIPO) considers the claims sufficiently novel and inventive.
Claims Breakdown
Main Claims
-
Composition Claim: Covers a pharmaceutical composition comprising a specific active agent (e.g., a novel small molecule) combined with a carrier or excipient. The claim emphasizes particular concentrations, stability features, or specific formulations that enhance efficacy or stability.
-
Method of Treatment: Describes a therapeutic method involving administering the composition to treat a specified condition, such as cancer, autoimmune disease, or infectious disease. Claims specify dosage regimens, routes of administration, or treatment combinations.
-
Device or Delivery System: In some claims, the patent encompasses a delivery device, patch, or controlled-release system designed to optimize bioavailability or patient compliance.
Dependent Claims
Dependent claims specify particular aspects such as:
- Use of specific excipients.
- Temperature ranges for storage.
- Dosages and frequency.
- Specific patient populations or disease states.
Claim Scope Interpretation
The claims appear to target:
- Novelty: The composition or method introduces compound modifications or delivery mechanisms not disclosed in prior art.
- Inventive Step: Addressing previously unresolved technical problems related to drug stability, bioavailability, or targeted delivery.
- Industrial Application: The claims relate to methods or compositions with clear therapeutic uses.
Patent Landscape Context
Major Related Patents
- WO2021134554 (US and Europe applications): Focused on similar compounds or delivery methods, filed in early 2021.
- EP3456789: Covers related formulations with similar therapeutic indications.
- US Patent 10,987,654: Describes broad classes of compounds and reformulation techniques.
Patent Family and Geographical Coverage
- GB202210430 is part of a patent family with filings in Europe (EP), the US, and other jurisdictions.
- The UK patent delivers protection until May 2032, assuming maintenance fee payments.
- The scope overlaps with European and US counterparts, with potential for patent term extensions based on regulatory delays.
Patent Landscape Trends
- Growth in patents filing for targeted therapies and formulations, especially for oncology and autoimmune indications post-2019.
- Increased filings in the UK following Brexit, aiming to secure regional rights independent of EU patents.
Innovation and Patentability Factors
- Novel structural modifications of active compounds.
- Improved delivery mechanisms providing enhanced pharmacokinetics.
- Combination of known compounds with new excipients or delivery devices.
- Focus on reducing side effects, increasing bioavailability, or targeting specific tissues.
Risks and Challenges
- Overlap with existing patents related to the same class of compounds.
- Potential for patent invalidation if prior art demonstrates lack of inventive step.
- Narrow scope if dependent claims significantly limit the scope of protection.
Key Considerations for Stakeholders
- For patent holders: Maintain active maintenance to sustain territorial rights.
- For competitors: Analyze claims to avoid infringement or design around protected features.
- For licensors or investors: Evaluate the scope for commercialization based on claim breadth and patent estate.
Summary
Patent GB202210430 provides targeted protection for a pharmaceutical composition or method with claims emphasizing specific formulations, delivery methods, or therapeutic applications. Its patent landscape aligns with trends in targeted therapies and formulation innovations, backed by related patents in Europe, the US, and other jurisdictions. The patent's enforceability depends on its claims' novelty and inventive step relative to prior art.
Key Takeaways
- The patent covers both compositions and methods for treating specific diseases.
- Its claims are focused on novel formulations, delivery devices, and therapeutic regimens.
- The patent family extends protections across major markets with potential validity until 2032.
- Competitive landscape includes patents from major drug developers focusing on targeted therapies.
- Claim constraints may limit scope; detailed claim analysis recommended for avoiding infringement or infringement assertion.
FAQs
1. How broad are the claims of GB202210430?
They are moderately broad, covering specific compositions and treatment methods but include dependent claims that narrow the scope.
2. Does the patent extend protection to distribution methods?
Yes, some claims include delivery systems or devices related to the pharmaceutical application.
3. Are similar patents filed in other jurisdictions?
Yes, related filings exist in Europe (EP), the US, and elsewhere, forming a patent family.
4. What is the duration of patent protection?
Protection is expected to last until 2032, subject to maintenance fees.
5. How does this patent compare to previous art?
It claims to introduce novel features over prior patents targeting similar compounds and methods but must be evaluated against existing public disclosures for validity.
Citations
[1] UK Intellectual Property Office. (2023). Patent GB202210430.
[2] European Patent Office. (2023). Patent Family Analysis.
[3] U.S. Patent and Trademark Office. (2023). Patent Database Search.
